Tesamorelin: The Only Lean-Mass Number in This Reference List

The short version

Tesamorelin is a synthetic copy of a hormone the brain uses to tell the pituitary gland to release growth hormone. It does not supply growth hormone. It amplifies the body's own pulses of it.

Growth hormone breaks down fat, and it does so most readily in the deep abdominal fat that surrounds the organs — visceral fat — rather than the fat directly under the skin.

It matters to this review for one reason. Of the four compounds here, it is the only one whose pooled trial data reports what happened to muscle. Across five randomised controlled trials, visceral fat fell, fat in the liver fell, and lean body mass went up by 1.42 kg ^[12].

The qualification is just as important. Those trials studied adults living with HIV who had developed a specific pattern of abnormal fat accumulation, and the drug is approved only for that condition. It was not being tested as a weight-loss agent, and the composition result cannot simply be transplanted onto people taking a different drug for a different reason.

What it is

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone — GHRH(1-44)-NH2 — carrying a trans-3-hexenoic acid group conjugated to the N-terminus. That N-terminal modification is the engineering: it resists cleavage by dipeptidyl peptidase-IV and extends plasma stability relative to the native hormone. It is supplied clinically as the acetate salt ^[13].

Regulatory position is narrow and precise. It was approved in the United States in 2010 to reduce excess abdominal fat in HIV-infected patients with antiretroviral-related lipodystrophy ^[13]. No approval exists outside that indication, which makes every other application — general visceral-fat reduction, non-HIV fatty liver disease, cognitive or anti-ageing use — off-label and investigational.

Two further status facts belong on the record. It is prohibited in sport under the World Anti-Doping Agency list as a growth-hormone-axis agent, both in and out of competition. And research-grade material sold for laboratory use is a different thing from the approved product: it does not carry the purity and potency oversight the approved medicine does, a distinction this review notes because it changes what published trial results can be said to apply to.

How it works

Tesamorelin binds the growth hormone-releasing hormone receptor on anterior-pituitary somatotroph cells, activating the Gs and adenylyl-cyclase cascade through cyclic AMP and protein kinase A, and stimulating the synthesis and pulsatile secretion of endogenous growth hormone. The growth hormone released in turn drives hepatic production of insulin-like growth factor-1, and the pair promote lipolysis preferentially in visceral adipose tissue ^[15].

The word doing the work in that description is endogenous. Because the drug amplifies the body's own pulsatile rhythm rather than supplying exogenous growth hormone at a flat concentration, its metabolic profile differs from recombinant growth hormone — which is the mechanistic reason a review of body composition treats it as a separate case rather than as a growth-hormone proxy.

The pharmacodynamics were measured directly in people without the target condition. In 13 healthy men, two weeks of tesamorelin at 2 mg per day raised mean overnight growth hormone by 0.5 micrograms per litre and insulin-like growth factor-1 by 181 micrograms per litre, while neither fasting glucose nor insulin-stimulated glucose uptake changed significantly ^[15]. That is a short, small study, and it is cited here for what it demonstrates: the axis moves as the mechanism predicts, and in that cohort it moved without a measurable insulin-sensitivity penalty.

Unlike the incretin agonists on this desk, this mechanism is not an appetite mechanism. Nothing in it reduces food intake. It changes where fat is mobilised from and what the growth-hormone axis is doing while that happens — which is precisely why its body-composition signature differs.

What the research shows

The pooled randomised evidence. A 2026 meta-analysis of five randomised controlled trials in HIV-associated lipodystrophy reported visceral adipose tissue down by a mean difference of 27.71 cm2, with a 95% confidence interval of -38.37 to -17.06; trunk fat down by 1.18 kg; hepatic fat fraction down by 4.28%; and lean body mass up by 1.42 kg. All four results reached significance, and the analysis reported no serious adverse events ^[12].

Read the units. Visceral adipose tissue in square centimetres is a cross-sectional imaging measurement at a defined anatomical level, not a scale reading. Trunk fat and lean body mass in kilograms are compartment masses. Hepatic fat as a fraction is an organ-specific measurement. This is what a body-composition result looks like, and it is the only one in this reference list.

The single-trial detail. A six-month randomised trial in JAMA enrolled 50 antiretroviral-treated adults with HIV, 28 assigned tesamorelin and 22 placebo, at 2 mg per day. The treatment effect on visceral fat was -42 cm2, and hepatic lipid-to-water percentage fell by a net -2.9% ^[14].

Durability and its limit. Across the 52-week programme — 273 participants on tesamorelin 2 mg per day against 137 on placebo — the visceral-fat reduction was sustained at -18% over 52 weeks. Visceral fat reaccumulated on discontinuation, and changes in glucose parameters over the year were not clinically significant ^[16].

Hepatic-safety position. The NIH LiverTox monograph assigns tesamorelin a likelihood score of E, meaning an unlikely cause of clinically apparent liver injury, with no reported attributable cases and no de novo serum-enzyme elevations in trials ^[13].

Five sources, and between them a visceral depot measured by imaging, a liver measured as a fat fraction, and two mass compartments in kilograms. It is a smaller and narrower evidence base than the incretin programmes reviewed elsewhere on this desk, and it is the only one that answers the question this desk is about.

Cautions, limits and what is not established

This review renders community-reported material only where the compound record carries a verified block of it. For tesamorelin the record carries none, so no anecdotal section appears on this page, and none has been improvised to fill the space.

What the record does carry is a set of documented limits, and for a compound with an attractive composition result they matter more than usual.

The indication is narrow and everything else is off-label. Approval covers excess abdominal fat in HIV-infected patients with antiretroviral-related lipodystrophy and nothing else ^[13]. General visceral-fat reduction, non-HIV fatty liver disease, cognitive use and anti-ageing use are all investigational.

The population is the constraint on generalisation. The pivotal efficacy trials enrolled HIV-positive adults on antiretroviral therapy ^[12][14]. Extending the result to people without HIV is mechanistically plausible and is not established by large randomised trials, and this review declines to treat plausibility as evidence.

The benefit is contingent on continued administration. Visceral fat reaccumulated after discontinuation in the 52-week programme ^[16].

Growth-factor exposure has a long-tail question attached. Stimulating the axis raises serum insulin-like growth factor-1, a growth factor. Trials showed no excess malignancy signal over 52 weeks ^[16], but long-term oncologic-safety data are limited and active malignancy is a labelled contraindication. A 52-week null result is a 52-week null result.

Glucose handling warrants monitoring, without overstating the signal. Modest glucose perturbation can occur, and monitoring is warranted where dysglycaemia or prediabetes is already present; the dedicated type 2 diabetes trial found no significant change in glycated haemoglobin, and the 52-week programme found glucose changes that were not clinically significant ^[16]. The healthy-volunteer study likewise found no significant change in fasting glucose or insulin-stimulated glucose uptake ^[15].

Practical and material limits. Injection-only administration constrains access, and material sold for laboratory research is not the studied product.

Where it fits in the muscle-sparing question

Tesamorelin is the answer to the muscle-sparing question that this reference list actually contains, and it arrives with three conditions attached that make it a far more interesting answer than a clean one.

Condition one: it is a real measurement. Lean body mass rose by 1.42 kg in pooled randomised data, alongside falls in visceral fat, trunk fat and hepatic fat ^[12]. That is not a scale reading, not an impedance estimate, and not an inference from a weight number. Four compartments were measured and reported separately.

Condition two: the mechanism explains it, and the explanation does not transfer. Growth hormone and insulin-like growth factor-1 are anabolic to lean tissue and lipolytic to adipose tissue; a drug that raises both is expected to move those two compartments in opposite directions ^[15]. That is a fundamentally different mechanism from turning appetite down. The incretin agonists on this desk create a large energy deficit through reduced intake, and a large energy deficit draws on lean tissue as well as fat unless something specifically opposes it. Tesamorelin's axis is that kind of opposing signal; a GLP-1 or GIP receptor is not.

Condition three: the population is not the population most readers have in mind. Participants were adults with HIV-associated lipodystrophy, a condition defined by abnormal fat distribution rather than by excess body weight, and the endpoint the trials were built around was abdominal fat, not weight loss ^[12][14]. The compound was not attempting a 20% reduction in body weight, and no result here suggests it could produce one. Comparing a +1.42 kg lean-mass figure from this literature against a -20.2% weight figure from an obesity trial ^[1] is comparing two studies that were asking different questions of different people.

The useful conclusion is a structural one rather than a ranking. Within this reference list, the compound that demonstrably moved lean mass upward is the one whose mechanism acts on the growth-hormone axis rather than on appetite, and it did so in a narrow clinical population at a scale of fat loss far smaller than the incretins produce. That is a genuine finding about mechanism, and it is not a licence to describe any compound on this desk as muscle-sparing during weight loss — because the trial that would test that proposition, in that population, on that endpoint, is not in this literature.